Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Fat Loss Stack: HGH Frag 176-191 + AOD-9604 for Metabolic Research

Back to library
peptide

Fat Loss Stack: HGH Frag 176-191 + AOD-9604 for Metabolic Research

10 min read
RESEARCH STACK
METABOLIC RESEARCH
FAT LOSS RESEARCH STACK
⚠️ GREY AREA
✅ RESEARCH CHEMICAL

⚠️ REGULATORY NOTICE — HGH FRAGMENT 176-191

HGH Fragment 176-191 occupies a regulatory grey area in the UK. It is not a licensed medicine and is not explicitly listed under the Misuse of Drugs Act 1971, but its structural relationship to human growth hormone means that the MHRA may apply broader enforcement discretion in some contexts. Pure Grade Labs supplies HGH Fragment 176-191 strictly as a research chemical for qualified laboratory research use only — not for human administration. No medical claims are made. No lifestyle, performance, or body composition claims are made. This article summarises published research literature for scientific educational purposes only.

Research Use Only. HGH Fragment 176-191 and AOD-9604 are sold strictly as research chemicals for in vitro and laboratory study. This article summarises published preclinical and clinical research literature. It does not constitute medical advice, a treatment protocol, or a recommendation for human use.

Fat Loss Research Stack: HGH Fragment 176-191 + AOD-9604 Metabolic Research

The Fat Loss Research Stack combines two compounds derived from the same region of the human growth hormone sequence: HGH Fragment 176-191 (the natural C-terminal fragment of the 191-amino acid GH sequence) and AOD-9604 (a stabilised synthetic analogue of the same region, with an additional N-terminal tyrosine). Both operate through β3-adrenergic receptor agonism to stimulate adipocyte lipolysis independently of IGF-1 elevation. Understanding the structural relationship, mechanistic similarities, and important regulatory differences between these two compounds is the scientific foundation for the research stack design.

Key Takeaways

  • HGH Frag 176-191: natural GH C-terminal sequence (CAS: 66004-57-7, MW: ~1817 Da) — no Tyr at N-terminus; direct lipolytic activity via β3-AR; no approved clinical dataset
  • AOD-9604: modified HGH Frag analogue with N-terminal Tyr addition (CAS: 221231-10-3) — Advanced Obesity Drug; tested through Phase IIb clinical trial (METAOD005); FDA GRAS status obtained for food supplement use
  • Shared mechanism: β3-adrenergic receptor (β3-AR) agonism → Gαs → ↑cAMP → PKA → hormone-sensitive lipase (HSL) activation → triglyceride hydrolysis
  • Neither compound elevates IGF-1 at any studied dose — separating the lipolytic from the anabolic GH pharmacology
  • AOD-9604 has substantially greater clinical evidence than HGH Frag 176-191 — a key distinction for research design
  • Research stack rationale: studying β3-AR lipolysis biology using both the natural sequence and its stabilised analogue in comparative or complementary protocols
β3-AR
Shared Target
Both compounds
0
IGF-1 Elevation
At any studied dose
300+
AOD Trial Subjects
METAOD005 Phase IIb
GRAS
AOD-9604 Status
FDA Generally Recognised as Safe

Research-grade HGH Fragment 176-191 and AOD-9604 from Pure Grade Labs — with full CoA and purity documentation.

View Research Catalogue →

Structural Relationship: Same Region, Different Modifications

Understanding the relationship between HGH Fragment 176-191 and AOD-9604 requires mapping them against the native human growth hormone sequence. Human GH is a 191-amino acid single-chain polypeptide. The GH sequence responsible for lipolytic activity is concentrated in the C-terminal domain — specifically the region spanning residues 176 to 191.

Property HGH Fragment 176-191 AOD-9604
Source sequence GH residues 176–191 (exact) GH 176–191 + Tyr at N-term
CAS number 66004-57-7 221231-10-3
Clinical data None (preclinical only) Phase IIb RCT (METAOD005)
IGF-1 elevation None (preclinical data) None (RCT confirmed)
Lipolytic mechanism β3-AR / HSL β3-AR / HSL
Regulatory status (UK) Grey area ⚠️ Research chemical ✅

The Tyr modification in AOD-9604 is not merely cosmetic. The tyrosine N-terminus provides: (1) greater stability against aminopeptidase N-terminal degradation; (2) a distinct pharmacokinetic profile from the native fragment; and (3) a distinct CAS identity and regulatory trajectory — enabling the Metabolic Pharmaceuticals/Calzada regulatory submission process that produced the Phase IIb METAOD005 trial. In research terms, HGH Frag 176-191 and AOD-9604 are similar but not identical tools for studying the same underlying β3-AR lipolysis mechanism.

Shared Mechanism: β3-AR Agonism and IGF-1-Free Lipolysis

The defining characteristic of both compounds is their ability to recapitulate GH’s lipolytic activity without engaging the GH receptor (GHR) — the receptor responsible for IGF-1 induction, protein synthesis, and the anabolic effects of native GH. The mechanism:

  1. GH fragment binds β3-adrenergic receptor (β3-AR) on adipocyte cell surface — a GPCR expressed predominantly in white and brown adipose tissue
  2. β3-AR couples to Gαs → adenylyl cyclase → ↑cAMP → protein kinase A (PKA) activation
  3. PKA phosphorylates hormone-sensitive lipase (HSL) at Ser563, Ser659, and Ser660, activating the enzyme
  4. Activated HSL hydrolyses stored triglycerides in lipid droplets → free fatty acids (FFAs) + glycerol released into circulation
  5. This entire cascade operates independently of the GH receptor — explaining why neither compound elevates IGF-1

The β3-AR specificity is significant for research design. β1-AR and β2-AR agonism (as produced by classical beta-agonists) affects cardiac function and causes tremor and tachycardia. β3-AR is expressed primarily in adipose tissue with relatively low cardiac expression, providing adipose-selective lipolytic activity — a property that distinguishes these GH fragments from non-selective sympathomimetics.

Research Context — The Ng et al. Discovery (2000): The lipolytic activity of the GH C-terminal fragment was first characterised by Ng FM and colleagues at Monash University (Ng et al., 2000, Am J Physiol Endocrinol Metab). The group had been investigating which region of the 191-aa GH sequence was responsible for its metabolic versus growth effects, hypothesising that the N-terminal and C-terminal domains might be separable pharmacophores for different biological activities. Their in vitro work confirmed that the C-terminal fragment (residues 177–191) produced lipolysis in fat cell cultures at concentrations as low as 100 ng/mL, while producing zero IGF-1 in hepatocyte cultures — confirming the pharmacophore separation. This work formed the scientific basis for the AOD-9604 development programme and the entire GH fragment lipolysis research field that followed.

AOD-9604: The METAOD005 Phase IIb Clinical Dataset

AOD-9604‘s clinical evidence base — which HGH Frag 176-191 lacks entirely — comes from the METAOD005 trial conducted by Metabolic Pharmaceuticals in Australia (2002–2004). This Phase IIb randomised, double-blind, placebo-controlled trial enrolled 300+ overweight and obese subjects across seven dose arms (0.25, 0.5, 1, 5, 10, 20, 30 mg/day SC injection) over 24 weeks.

Key METAOD005 findings:

  • 1 mg/day arm: Statistically significant fat mass reduction versus placebo at 24 weeks, with the largest treatment effect observed in this dose group
  • Dose-response: Non-linear — fat loss at 1 mg was not exceeded by doses up to 30× higher, indicating receptor saturation at the 1 mg dose level
  • IGF-1: No elevation at any dose across 24 weeks — confirming the preclinical β3-AR/non-GHR mechanism in a human clinical setting
  • Glucose metabolism: No adverse effects on fasting glucose or insulin at any dose — a clean metabolic safety profile
  • FDA GRAS status: AOD-9604 subsequently received Generally Recognised As Safe (GRAS) notice from the FDA for use in food supplement applications — a regulatory outcome reflecting the safety data accumulated across the clinical programme

The METAOD005 trial did not achieve Phase III status — Metabolic Pharmaceuticals discontinued the programme following Phase IIb, likely due to commercial rather than safety/efficacy reasons. The trial nonetheless provides the highest quality clinical evidence for the β3-AR GH fragment lipolysis mechanism in human subjects.

HGH Fragment 176-191: Preclinical Research Profile

⚠️ Grey area compound — research use only, no medical claims.

HGH Fragment 176-191 (CAS: 66004-57-7) is the unmodified natural sequence from human GH at positions 176–191, with a disulphide bond between Cys182 and Cys189 that is present in the native GH structure. This disulphide bridge is absent in AOD-9604 (which uses the same sequence but in linear form without the Cys residues or with reduced/capped cysteines depending on the synthesis).

In the preclinical literature (primarily Heffernan et al. and Ng et al. rodent studies), HGH Fragment 176-191 demonstrates:

  • Lipolysis induction in isolated fat cell cultures and in vivo rodent adipose tissue models, comparable to AOD-9604 at equivalent molar doses
  • No GHR binding in receptor competition assays — confirming the mechanism is not mediated through the full GH receptor
  • No IGF-1 elevation in rodent studies at doses producing significant lipolytic effects
  • Accelerated fat oxidation in fasted rodents measured by indirect calorimetry

The absence of clinical data for HGH Frag 176-191 (compared to AOD-9604’s Phase IIb programme) reflects commercial rather than mechanistic differences — the clinical development was conducted on AOD-9604 specifically because the Tyr modification enabled a cleaner intellectual property position for Metabolic Pharmaceuticals. The preclinical lipolysis data for the unmodified fragment is comparable to that of AOD-9604.

Pure Grade Labs stocks HGH Fragment 176-191 and AOD-9604 with full HPLC purity data for research use.

Browse Research Chemicals →

Research Note — CAS Number Mislabelling Risk: A practical problem in the GH fragment research literature is that HGH Fragment 176-191 (CAS: 66004-57-7) and AOD-9604 (CAS: 221231-10-3) are sometimes confused or mislabelled by suppliers. They are structurally similar but chemically distinct compounds with different CAS numbers, different molecular weights, and different regulatory histories. Researchers should verify CAS number, MW confirmation by MS, and amino acid sequence identity in the CoA before initiating any study. Cross-checking the listed CAS against published Ng et al. (2000) data for AOD-9604 or Heffernan et al. (2000) data for the unmodified fragment will confirm which compound is in hand. Pure Grade Labs provides CAS-specific CoA documentation for both compounds.

Stack Research Rationale: Comparative and Complementary Protocols

The Fat Loss Research Stack supports two distinct preclinical research approaches:

Comparative design: HGH Frag 176-191 and AOD-9604 administered in parallel arms at equivalent molar doses to directly compare the lipolytic efficacy of the natural sequence versus the Tyr-modified analogue. This head-to-head design quantifies whether the N-terminal Tyr modification produces a meaningful pharmacodynamic difference — a question with implications for future GH fragment drug development.

Mechanistic validation design: Both compounds administered to confirm that the shared β3-AR/cAMP/HSL lipolysis mechanism produces comparable results across two structural variants — providing convergent evidence for the mechanism independent of any single compound’s idiosyncrasies.

In either design, having both compounds sourced from the same qualified supplier with batch-matched purity data is important for minimising confounding variables.

Frequently Asked Questions

What is the difference between HGH Fragment 176-191 and AOD-9604?

AOD-9604 is the N-terminal tyrosine-modified form of HGH Fragment 176-191. Both contain the GH sequence from residues 176–191; AOD-9604 has an additional Tyr at position 0. They share the β3-AR lipolysis mechanism, but AOD-9604 has a Phase IIb clinical trial (METAOD005) and FDA GRAS status. HGH Frag 176-191 has only preclinical data and occupies a regulatory grey area in the UK.

Why doesn’t HGH Fragment elevate IGF-1?

The N-terminal domain of GH (residues 1–43 approximately) is responsible for GH receptor (GHR) binding and JAK2/STAT5 signalling that drives IGF-1 induction. The C-terminal fragment (176–191) lacks the GHR-binding pharmacophore entirely and therefore does not activate the IGF-1 production pathway. Its lipolytic activity is via a separate receptor system (β3-AR), explaining the IGF-1-free lipolysis profile.

What was the optimal AOD-9604 dose in the METAOD005 trial?

The 1 mg/day subcutaneous injection arm produced the greatest fat mass reduction versus placebo. Doses of 5, 10, 20, and 30 mg/day did not produce proportionally greater fat loss — indicating β3-AR saturation at the 1 mg dose level. This non-linear dose-response is consistent with receptor saturation pharmacology and is the established reference dose for AOD-9604 in research protocols.

Why is HGH Fragment 176-191 in a regulatory grey area?

HGH Fragment 176-191 is structurally derived from human growth hormone — a Schedule 4 controlled substance under the Misuse of Drugs Act in a sporting context and a hormone regulated under the Human Medicines Regulations. The fragment itself is not explicitly scheduled or licensed, but its GH derivation places it in an ambiguous regulatory position. The MHRA may apply discretionary enforcement. Pure Grade Labs supplies it strictly as a research chemical with appropriate compliance documentation.

Summary

The Fat Loss Research Stack pairs two structurally related GH fragment compounds that target the same β3-AR lipolysis mechanism through slightly different molecular structures. HGH Fragment 176-191 represents the natural unmodified sequence — useful for studying the native pharmacophore. AOD-9604 provides the most clinically validated GH fragment dataset available, with Phase IIb RCT data confirming the mechanism, the dose-response profile, and the zero-IGF-1-elevation safety characteristic in humans. Together they offer a research toolkit for investigating adipocyte lipolysis biology, IGF-1-independent fat metabolism, and β3-AR pharmacology in preclinical and comparative models — all within the established IGF-1-separable GH fragment mechanistic framework.

Research-grade HGH Fragment 176-191 and AOD-9604 from Pure Grade Labs — both with full CoA.

Shop Research Chemicals →

References

  1. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501–507. PMID: 10950819
  2. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274–278. PMID: 11146367
  3. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology. 2001;142(12):5182–5189. PMID: 11713213
  4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest. 2013;36(5):369–375. PMID: 22955148
  5. Landgraf R, Landgraf-Leurs MM, Weissmann A, et al. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13(2):99–104 [Background reference for GH/fat relationship]

Disclaimer: This article is published for educational and research purposes only. HGH Fragment 176-191 and AOD-9604 are sold by Pure Grade Labs strictly as research chemicals, not for human consumption or therapeutic use. No medical claims, body composition claims, or lifestyle claims are made for either compound. HGH Fragment 176-191 occupies a regulatory grey area in the UK — researchers must ensure full compliance with applicable regulatory requirements. All research use must comply with applicable institutional and regulatory requirements.